SciBX: Science-Business eXchange Contents: July 19 2012, Volume 5 / Issue 28

TABLE OF CONTENTS July 19 2012, Volume 5 / Issue 28 Analysis Cover Story Targets and Mechanisms Tools The Distillery: Therapeutics Autoimmune disease Cancer Gastrointestinal disease Hematology Infectious disease Musculoskeletal disease Neurology Ophthalmic disease Various The Distillery: Techniques Assays and screens Computational models Disease models Drug delivery Drug platforms Advertisement BioPharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery The June 2012 issue of BioPharma Dealmakers showcases companies with partnering opportunities within the academic and vaccine fields in the U.S and abroad. This week, find out about how you can collaborate with GlaxoSmithKline Vaccines.     SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top PI3Kδ turns schizophrenic Tim Fulmer doi:10.1038/scibx.2012.718 NIH researchers have linked phosphoinositide 3-kinase-δ to neuregulin signaling and shown that inhibiting the kinase improved behavior in rodent models of schizophrenia. The findings could offer a way to finally target the neuregulin pathway. Full Text | PDF Targets and Mechanisms Top OutFOXing tumors Tracey Baas doi:10.1038/scibx.2012.719 Mount Sinai and Case Western researchers have found a new use for the dopamine receptor antagonist trifluoperazine: restoring the sensitivity of tumors to EGFR inhibitors. The key is trifluoperazine's off-target activity inhibiting the nuclear export of the tumor suppressor FOXO1. Full Text | PDF Getting AGRP on obesity Kai-Jye Lou doi:10.1038/scibx.2012.720 New York researchers have identified GPR17 as a potentially druggable target on AGRP neurons, which are known to regulate factors relevant to obesity. The findings open up a new pathway to mine for therapeutic strategies against a cell population for which earlier targeting strategies have had little success. Full Text | PDF Tools Top SEAing change in R&D Kai-Jye Lou doi:10.1038/scibx.2012.721 UCSF, SeaChange and Novartis have developed a computational approach for large-scale, automated prediction of binding interactions between small molecules and targets that have been associated with adverse drug reactions. The method could help companies improve R&D productivity by pointing to safety signals and helping prioritize candidates in silico. Full Text | PDF Distillery: Therapeutics Autoimmune disease Top Guanine nucleotide binding protein-like 3 (GNL3; nucleostemin) doi:10.1038/scibx.2012.722 Genomewide association studies identified mutations in the GNL3 gene that could help predict susceptibility to osteoarthritis. Full Text | PDF Cancer Top Death effector domain containing (DEDD) doi:10.1038/scibx.2012.723 Mouse and patient studies suggest enhancing DEDD signaling could help treat and prevent cancer metastasis. Full Text | PDF Signal transducer and activator of transcription 3 (STAT3) doi:10.1038/scibx.2012.724 In vitro and mouse studies suggest inhibiting STAT3 could enhance antitumor immunity to help treat MCL. Full Text | PDF AXL receptor tyrosine kinase (AXL; UFO) doi:10.1038/scibx.2012.725 In vitro, patient sample and mouse studies suggest inhibiting AXL could help treat epidermal growth factor receptor (EGFR) inhibitor–resistant NSCLC. Full Text | PDF BRAF doi:10.1038/scibx.2012.726 Patient and cell culture studies suggest NSCLC patients with inactivating BRAF mutations may respond to Sprycel dasatinib. Full Text | PDF Jun (AP1) proto-oncogene doi:10.1038/scibx.2012.727 Mouse studies identified a Jun mRNA–targeting DNAzyme that could help treat SCC and BCC. Full Text | PDF Gastrointestinal disease Top Epidermal growth factor receptor (EGFR) doi:10.1038/scibx.2012.728 Mouse and infant studies suggest amniotic fluid could be used to prevent necrotizing enterocolitis (NEC). Full Text | PDF Hematology Top CD3e molecule-ε CD3-TCR complex (CD3E) doi:10.1038/scibx.2012.729 Mouse studies suggest anti-CD3E mAbs could help treat Omenn syndrome, a form of severe combined immunodeficiency that is associated with mutations in recombination activating genes (RAGs). Full Text | PDF Infectious disease Top Plasmodium falciparum lysyl-tRNA synthetase (Pfkrs1) doi:10.1038/scibx.2012.730 In vitro and cell culture studies suggest inhibiting Pfkrs1 could help treat liver- and blood-stage malarial infections. Full Text | PDF Musculoskeletal disease Top Bone morphogenetic protein 2 (BMP2); BMP4; bone morphogenetic protein receptor type IA (BMPR1A) doi:10.1038/scibx.2012.731 In vitro and mouse studies suggest a BMPR1A-Fc fusion protein could help treat bone-related disorders such as osteoporosis. Full Text | PDF Neurology Top Caspase-6 (CASP6; MCH2) doi:10.1038/scibx.2012.732 In vitro and cell culture studies identified a peptide-based inhibitor of CASP6, which is associated with neurodegenerative diseases such as AD and HD. Full Text | PDF Neuritin (NRN) doi:10.1038/scibx.2012.733 Rat studies suggest increasing NRN levels could help treat depression. Full Text | PDF Epoxide hydrolase doi:10.1038/scibx.2012.734 Rat studies suggest inhibitors of soluble epoxide hydrolase could help treat pain associated with diabetic neuropathy. Full Text | PDF Protein kinase B (PKB; PKBA; AKT; AKT1) doi:10.1038/scibx.2012.735 In vitro and mouse studies identified an AKT activator that could help treat neurological conditions including stroke. Full Text | PDF μ-Opioid receptor (OPRM1; MOR) doi:10.1038/scibx.2012.736 Mouse studies identified MOR-activating endomorphin-1 analogs that could help treat pain. Full Text | PDF Phosphoinositide 3-kinase-δ (PI3Kδ) doi:10.1038/scibx.2012.737 In vitro, rat and patient genetic studies suggest inhibitors of PI3Kd could help treat schizophrenia. Full Text | PDF Ophthalmic disease Top Opticin (OPTC) doi:10.1038/scibx.2012.738 Mouse studies suggest OPTC could decrease neovascularization to help treat retinopathy. Full Text | PDF Various Top Delta-like 4 (DLL4) doi:10.1038/scibx.2012.739 Mouse studies suggest antagonizing DLL4 could help treat atherosclerosis and metabolic diseases. Full Text | PDF Distillery: Techniques Assays and screens Top In vitro blood brain barrier (BBB) with pluripotent stem cells doi:10.1038/scibx.2012.740 In vitro studies suggest human pluripotent stem cells could be used to screen for BBB-modulating compounds. Full Text | PDF Computational models Top Correction and assembly of single-molecule sequencing reads doi:10.1038/scibx.2012.741 A computational approach for correcting errors in long-read, single-molecule sequencing could aid in developing applications of the technology for biomedical discovery and guiding treatment. Full Text | PDF Disease models Top Induced pluripotent stem (iPS) cells derived from patients with Huntington's disease (HD) doi:10.1038/scibx.2012.742 In vitro studies suggest iPS cell lines generated from patients with HD could help identify new therapeutics. Full Text | PDF Mouse model of acrodermatitis enteropathica doi:10.1038/scibx.2012.743 A mouse model of acrodermatitis enteropathica could help identify therapeutics for the rare lethal metabolic disorder that impairs zinc uptake. Full Text | PDF Drug delivery Top Adeno-associated virus (AAV) expression of an anti-nicotine antibody doi:10.1038/scibx.2012.744 Persistent expression of an anti-nicotine antibody using an AAV vector could help prevent nicotine addiction. Full Text | PDF Drug platforms Top Genetically corrected induced pluripotent stem (iPS) cell–derived mesoangioblasts for limb-girdle muscular dystrophy doi:10.1038/scibx.2012.745 Genetically corrected mesoangioblasts derived from iPS cells could be useful for treating limb-girdle muscular dystrophy, which is caused by mutations in the sarcoglycan-α (SGCA) gene. Full Text | PDF You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.